



## Support the Prompt Pay Discount Legislation to help ensure the efficient distribution of life-saving cancer care drugs

The “prompt pay discount” legislation (H.R. 905 / S. 733) is a common-sense effort to correct a problem that currently threatens the efficient distribution of cancer care drugs across the nation. By ensuring more appropriate payment amounts for cancer care drugs and biologicals under Medicare Part B would help protect access to the nation’s community-based cancer centers, which provide treatment to more than 80 percent of the nation’s new cancer patients.

The problem lies inside a formula which factors discount agreements extended between manufacturers and wholesalers into a reimbursement rate amount intended to reimburse community based providers who purchase drug solutions. Including any prompt pay discounts within provider drug reimbursement to the practice artificially lowers reimbursement to the cancer care provider who is in many instances underwater and in-effect subsidizing the provision of these drugs to their cancer patients. This was obviously not the intent of Congress when creating the ASP calculation.

This effort enjoys wide support across patient groups, community oncologists, specialty distribution organizations, and pharmaceutical manufacturers, including the following organizations: the National Patient Advocacy Foundation, ACCC, Amerisource Bergen, ASCO, COA, Curascript Specialty Distribution, HDMA, Health Coalition, Inc., Patient Services Incorporated, SGO, UPMC Cancer Centers, Amgen, Johnson and Johnson, and US Oncology / McKesson.

### The Reality:

- **ASP + 6%** for our practices is actually **ASP – 2%**

ASP  
+ 6% (MMA)  
– 2% (prompt pay discount)  
– 1% (two quarter lag)  
– 5% (uncollectable co-insurance)

---

**ASP – 2%**

**Members: Please consider co-sponsoring the Prompt Pay Discount Legislation (H.R. 905 / S. 733) to help ensure the efficient distribution of life-saving cancer care drugs.**